Tovorafenib for treating relapsed or refractory paediatric low-grade glioma with BRAF fusion or rearrangement or BRAF V600 mutation in people 6 months and over [ID6557]
In development
Reference number: GID-TA11693
Expected publication date: TBC
To appraise the clinical and cost effectiveness of Tovorafenib within its marketing authorisation for treating glioma